Managers / Q3 2021 · view latest →
Aviva Holdings Ltd.
CIK 0001603935 · ALBANY FINANCIAL CENTER, SUITE 207, LEWIS DRIVE N7776, NEW PROVIDENCE, C5, 00000 · 407-909-9970
Summary
Aviva Holdings Ltd. reported $709M in U.S.-listed holdings across 7 positions for Q3 2021.
The portfolio is heavily concentrated: Mirati Therapeutics alone accounts for 78.3% of reported value.
Compared with Q2 2021, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 97.7% · $693M
- US DOMESTIC · 1.8% · $13M
- ADR · 0.4% · $3M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| TNGXTANGO THERAPEUTICS INC | NEW | +27.0K | 27.0K | +$349,000 | $349,000 |
| PAMPAMPA ENERGIA S A | TRIMMED | −1.02M | 182.0K | +$3M | $3M |
| INSEEGO CORP | ADDED | +1.07M | 20.65M | −$60M | $138M |
| MIRATI THERAPEUTICS INC | HELD | +0 | 3.14M | +$48M | $555M |
| INSEEGO CORP | HELD | +0 | 24.46M | −$7M | $13M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MIRATI THERAPEUTICS INC | COMMON | 78.28% | $555M | 3.14M |
| 2 | INSEEGO CORP | COMMON · Note 3.250%5/0 | 21.23% | $150M | 45.10M |
| 3 | PAMPAMPA ENERGIA S A | SPONS ADR LVL I | 0.45% | $3M | 182.0K |
| 4 | TNGXTANGO THERAPEUTICS INC | COMMON | 0.05% | $349,000 | 27.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2024 | $21M | 1 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $41M | 2 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $26M | 2 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $13M | 2 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $13M | 2 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | Under review | 5 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | Under review | 5 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $143M | 5 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $174M | 5 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 6 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $278M | 7 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $379M | 7 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $615M | 7 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $709M | 7 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $724M | 6 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $752M | 4 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.0B | 4 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $767M | 4 | Nov 17, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $643M | 6 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $439M | 5 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019REVEALED | $669M | 6 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $370M | 6 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $478M | 6 | Aug 28, 2019 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2019 | $456M | 9 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $317M | 10 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 3 additional managers.
- Braslyn Ltd.28-17341
- Golden Harbor Ltd.28-20130
- Shelton Ventures Inc.28-17344
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.